MOTS-C

Specifications MOTS-C

Company: Hilma Biocare
Group: Injection/powder
Active Half-life (min): 7 to 30
Subgroup: Peptide hormone
Dosage: 10 mg
Application (Men): 200-1000 mcg
Product pack:  1 vial
Content (active): MOTS-C
Retains water: No
Aromatization: No

DESCRIPTION

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino acid mitochondrial signaling peptide that regulates metabolism. It switches cells to fat burning, improves insulin sensitivity, increases endurance, and slows aging. It is actively used to optimize metabolism and energy production.

MOTS-c is synthesized directly in mitochondria (the “power plants” of cells) and is transported to the nucleus, regulating gene expression and adapting the body to metabolic stress. Under natural conditions, MOTS-c levels in the body increase in response to exercise, leading some studies to consider the peptide an “exercise mimic.”

APPLICATION

MOTS-c activates AMPK (the cellular energy sensor), which helps reduce insulin resistance, regulates blood sugar levels, and promotes fat breakdown (lipolysis), which holds promise for the treatment of type 2 diabetes and obesity. MOTS-c enhances physical performance, improves muscle adaptation to exercise, and accelerates recovery after exercise or injury.

It is used in anti-aging therapy, supports muscle and bone health, and reduces chronic inflammation. It slows down age-related changes by protecting cells from oxidative stress, reducing inflammation, and improving mitochondrial function. It is used for chronic fatigue, helping the body use energy efficiently. Research also indicates a positive role for the peptide in protecting cardiomyocytes and improving endothelial function, which has a beneficial effect on the cardiovascular system.

DOSAGE AND ADMINISTRATION

The lyophilized form of MOTS-c is typically injected subcutaneously into the fatty tissue (often in the abdomen or thigh). The frequency of injections is determined by a physician (usually administered intermittently, for example, 1-2 times per week).

The initial recommended dosage is 2.5 mg per injection. Depending on the treatment goal, the dosage may be increased to 5 mg, and in cases of intensive therapy, to 10 mg per injection. The treatment regimen and duration depend on the treatment goals. The standard course lasts 4-6 weeks, while the maintenance course lasts up to 10 weeks with weekly administration.

Daily use is not recommended. Injections of 5-10 mg trigger transcriptional changes in the cell nucleus that last for 3-7 days, so infrequent (1-3 times per week) high doses are more effective than daily low doses. The effect is cumulative: the first subjective changes are usually observed within 1-2 weeks, with a full metabolic shift occurring within 3-4 weeks of regular use.

To achieve a synergistic effect, MOTS-c can be taken in combination with other peptides, such as BPC-157 or GLP-1 agonists. Consult your doctor regarding individual dosage, administration schedule, and drug compatibility.

CONTRAINDICATIONS

MOTS-c is not recommended for use during pregnancy and breastfeeding. Other contraindications include age under 21, tumors, acute infections, and active autoimmune processes. It is not recommended to take it with alcohol or antibiotics.

SIDE EFFECTS

MOTS-c is considered a relatively safe drug; side effects are rare. In some cases, increased heart rate and insomnia may occur. MOTS-c is an endogenous peptide produced by human mitochondria. This results in high biocompatibility, low immunogenicity, and no systemic toxicity in preclinical studies. Injection site reactions are minimal, typical for subcutaneous peptide administration. Hypoglycemia is theoretically possible when combined with hypoglycemic medications: in this case, regular blood sugar monitoring is recommended.